Normunity is a biotechnology company developing anti-cancer therapies that target novel tumor-specific mechanisms to engage T cells and suppress immune evasion in solid tumors.

A2 Biotherapeutics, Inc. develops novel cell therapies using its Tmod™ platform to selectively target tumor cells while sparing normal cells in cancer treatment.

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Nura Bio Inc. develops neuroprotective therapies for neurological diseases, with a focus on advancing their lead candidate, a brain-penetrant SARM1 inhibitor.

Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.

OrsoBio, Inc. is a clinical-stage biopharmaceutical company developing novel mitochondrial protonophore therapies targeting obesity and associated metabolic disorders.

Pathalys Pharma is a biopharmaceutical company developing advanced therapeutics for end-stage kidney disease (ESKD).

Seismic Therapeutic is a biotechnology firm specializing in the development of immunology drugs using a machine learning-enabled platform to advance its biologics pipeline through clinical trials.

EyeBio is a clinical-stage ophthalmology biotechnology company focused on developing therapies for sight-threatening eye diseases and has expanded its Series A funding to $130 million.

OrsoBio, Inc. is a clinical-stage biopharmaceutical company developing novel mitochondrial protonophore therapies targeting obesity and associated metabolic disorders.

Tentarix Biotherapeutics is a biotechnology company that uses its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics.